References
- PittsPJopenFDA: An Open QuestionTher Innov Regul Sci201412
- MorratoEHLingSBThe Drug Safety and Risk Management Advisory Committee: a case study of meeting frequency, content, and outcomes before and after FDAAAMed Care2012501197098623047787
- U.S. Food and Drug AdministrationApproved Risk Evaluation and Mitigation Strategies (REMS) [Updated July 7, 2014]. Available from: http://www.fda.gov/Drugs/DrugSafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm111350.htmAccessed February 4, 2015
- FrankCHimmelsteinDUWoolhandlerSEra of faster FDA drug approval has also seen increased black-box warnings and market withdrawalsHealth Aff (Millwood)20143381453145925092848
- Guideline on Good Pharmacovigilance Practices (GVP) Module V – Risk Management Systems (Rev 1)United KingdomEuropean Medicines Agency and Heads of Medicines Agencies2014
- Guideline on Good Pharmacovigilance Practices (GVP) Module XVI–Risk Minimisation Measures: Selection of Tools and Effectiveness Indicators (Rev 1)United KingdomEuropean Medicines Agency and Heads of Medicines Agencies2014
- U.S. Food and Drug AdministrationPDUFA Reauthorization Performance Goals and Procedures. Fiscal Years 2013 through 2017
- U.S. Food and Drug AdministrationREPORT: Standardizing and Evaluating Risk Evaluation and Mitigation Strategies (REMS)2014
- SmithMYMorratoEAdvancing the field of pharmaceutical risk minimization through application of implementation science best practicesDrug Saf201437856958025005707
- Practical Approaches to Risk Minimisation for Medicinal Products: Report of CIOMS Working Group IXGeneva, SwitzerlandCouncil for International Organizations of Medical Sciences2014
- JunodSWFDA and Clinical Drug Trials: A Short History [Updated July 7, 2014]. Available from: http://www.fda.gov/AboutFDA/WhatWeDo/History/Overviews/ucm304485.htmAccessed February 4, 2015
- LevinsonDRFDA Lacks Comprehensive Data To Determine Whether Risk Evaluation and Mitigation Strategies Improve Drug Safety (OEI-04-11-00510)Washington, DCHealth and Human Services, Office of Inspector General2013
- Department of Health and Human Services, Food and Drug AdministrationRisk Evaluation and Mitigation Strategy Assessments: Social Science Methodologies to Assess Goals Related to Knowledge: Public WorkshopFed Regist201277862629226294
- Engelberg Center for Health Care Reform at BrookingsStrengthening Risk Evaluation and Mitigation Strategies (REMS) Through Systematic Analysis, Standardized Design, and Evidence-Based Assessment: Meeting SummaryWashington, DC2013
- Department of Health and Human Services, Food and Drug AdministrationREPORT: Standardizing and Evaluating Risk Evaluation and Mitigation Strategies (REMS)92014
- JaziehARFuture of translational research: why go pragmatic?Pragmatic Obs Res2011201114
- GlasgowRERileyWTPragmatic measures: what they are and why we need themAm J Prev Med201345223724323867032
- LustriaMLNoarSMCorteseJVan SteeSKGlueckaufRLLeeJA meta-analysis of web-delivered tailored health behavior change interventionsJ Health Commun20131891039106923750972
- GridchynaICloutierAMNkengLCraigCFriseSMorideYMethodological gaps in the assessment of risk minimization interventions: a systematic reviewPharmacoepidemiol Drug Saf201423657257924616240
- Center for Drug Evaluation and Research (CDER)Center for Biologics Evaluation and Research (CBER)Guidance for Industry Format and Content of Proposed Risk Evaluation and Mitigation Strategies (REMS), REMS Assessments, and Proposed REMS Modifications 2009 (Draft Guidance)Silver Spring, MDU.S. Department of Health and Human Services, Food and Drug Administration2009
- U.S. Food and Drug AdministrationGuidance for Industry: Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment2005 Available from: http://www.fda.gov/cber/guidelines.htm#pharmaAccessed April 7, 2005
- PeekCJGlasgowREStangeKCKlesgesLMPurcellEPKesslerRSThe 5 R’s: an emerging bold standard for conducting relevant research in a changing worldAnn Fam Med201412544745525354409
- GluckMERadomskiLThe AcademyHealth Listening Project Report: Improving the Evidence Base for Medicare PolicymakingWashington, DCAcademyHealth2014
- LooneyWFDA’s patient outreach: finding ties that bindPink Sheet2014701
- Institute P-CORWhat We Mean by Engagement2014 Available from: http://www.pcori.org/content/what-we-mean-engagementAccessed October 30, 2014
- MilliganPABrownMJMarchantBModel-based drug development: a rational approach to efficiently accelerate drug developmentClin Pharmacol Ther201393650251423588322
- LipskyMSSharpLKFrom idea to market: the drug approval processJ Am Board Fam Pract200114536236711572541
- HughesMIngleseJKurtzAEarly drug discovery and development guidelines: for academic researchers, collaborators, and start-up companiesSittampalamGSCoussensNPNelsonHAssay Guidance Manual [Internet]Bethesda, MDEli Lilly & Company and the National Center for Advancing Translational Sciences20122004
- Patient-Centered Outcomes Research InstitutePCORI Engagement Rubric with Table2014 Available from: http://www.pcori.org/assets/2014/08/PCORI-Engagement-Rubric-with-Table.pdfAccessed October 12, 2014
- FDAFDA and patient groups take center stage as part of effort to accelerate #Path2Cures [press release]71120142014
- AlbrightKGechterKKempeAImportance of mixed methods in pragmatic trials and dissemination and implementation researchAcad Pediatr201313540040724011744
- DamschroderLJAronDCKeithREKirshSRAlexanderJALoweryJCFostering implementation of health services research findings into practice: a consolidated framework for advancing implementation scienceImplement Sci200945019664226
- TonelloMThe Business Case for Corporate Social ResponsibilityThe Harvard Law School Forum on Corporate Governance and Financial Regulation2011 Available from: http://blogs.law.harvard.edu/corpgov/2011/06/26/the-business-case-for-corporate-social-responsibility/Accessed February 17, 2015